Vaxcyte shares are trading higher on Monday, April 13, 2026, as investors look ahead to a scheduled management fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET. Conference appearances can act as near-term catalysts in clinical-stage biotech when traders expect updates on trial progress, timelines, and regulatory strategy. (investors.vaxcyte.com)

The backdrop for today’s bid is Vaxcyte’s March 23, 2026 announcement that it completed enrollment in two key Phase 3 studies for VAX-31 in adults: OPUS-1 (about 4,000 participants) and OPUS-2 (about 1,300 participants). The company said OPUS-1 topline safety, tolerability and immunogenicity data are expected in the fourth quarter of 2026, while OPUS-2 results are expected in the first half of 2027; enrollment in OPUS-3 is ongoing with results expected in the first half of 2027. (investors.vaxcyte.com)

Near-term attention is on whether management provides incremental color on the OPUS program execution (site progress, follow-up timelines, and statistical framing) and how the company is thinking about a planned BLA submission path in adults. Any clarification around trial operations and next milestones could influence expectations for the 2026–2027 catalyst calendar and, in turn, the stock’s risk/reward heading into the OPUS-1 readout window. (investors.vaxcyte.com)